Center to Accelerate Population Research in Alzheimer's (CAPRA)

加速阿尔茨海默病人群研究中心 (CAPRA)

• 批准号: 10222554
• 负责人: Julie PW Bynum
• 金额: $ 86.66万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10222554
• 关键词: Address; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Archives; Area; Behavioral Risk Factor Surveillance System; Caring; Communities; Complex; Consult; Consumption; Country; Data; Data Sources; Dementia; Diffusion; Discipline; Disease; Drug Prescriptions; Economic Policy; Economics; Funding; Future; Goals; Government; Health; Health Policy; Health Services; Health Services Accessibility; Health system; Healthcare; Home; Individual; Infrastructure; Interdisciplinary Study; International; Investigation; Investments; Knowledge; Lead; Leadership; Link; Long-Term Care; Medicare; Methods; Michigan; National Health and Nutrition Examination Survey; Outcome; Personal Satisfaction; Persons; Pilot Projects; Policies; Policy Maker; Population; Population Research; Positioning Attribute; Prevention; Program Development; Public Health; Public Policy; Quality of Care; Ramp; Research; Research Personnel; Research Training; Resource Allocation; Resource Development; Resources; Risk; Science; Societies; Surveys; System; Time; Training; Universities; base; cardiovascular risk factor; cost; design; drug quality; effective therapy; end of life; falls; health care delivery; health care service organization; improved outcome; innovation; multidisciplinary; new technology; novel diagnostics; novel therapeutics; organizational structure; population based; prevent; social; tool

Project Abstract (Overall) The population with Alzheimer’s Disease and related dementias (AD/ADRD) globally is expected to nearly triple by 2050. With few effective treatments either to prevent the disease or slow its progression, we are currently limited to managing established disease and minimizing further negative outcomes, at a cost of $200 billion per year. The National Alzheimer’s Project Act (NAPA) was passed with the goal of reducing the burden of AD/ADRD, not just for persons with dementia but also for the society at large, including the social, economic, and health system effects. There are large gaps in our knowledge about how policy-makers, public health planners and healthcare organizations can best prepare for and respond to the broad population effects of AD/ADRD as we await a cure. The proposed Center to Accelerate Population Research in Alzheimer’s (CAPRA) at the University of Michigan will be focused on science that informs government and healthcare organization actions to address the negative impacts of dementia on the health and financial well-being of individuals and the population. Our focus on public policy and healthcare for persons with dementia falls into four inter-related themes: 1) healthcare delivery and policy impact on outcomes and quality of care, 2) diffusion of new technologies, 3) disparities in quality and access to care, and 4) innovative applications of population data that inform allocation of resources and program development. The CAPRA leadership team is uniquely positioned to leverage its own expertise across these themes and the depth of institutional expertise at the University of Michigan across health services, economic, and population research to accelerate and expand population-based observational AD/ADRD research. The overarching goal for CAPRA is that it will serve as a national resource to enable and expand research by current and future leaders in the study of healthcare delivery, economics, and policies to reduce the burden of AD/ADRD locally, nationally, and internationally. To do so, the Center will act as an “on-ramp” to fast-track junior and established investigators transitioning into AD/ADRD research by funding pilot studies, providing research training and tools, giving access to unique secondary data relevant to AD/ADRD, and developing networks of experts with whom to consult and collaborate. CAPRA seeks to become the leading national resource to promote and accelerate studies that aim to reduce the social, economic, and health burden of AD/ADRD on the population. The research that emanates from this new Center will have real-world implications for health systems, payers, and policymakers as they struggle with designing effective policies to improve outcomes for the growing population with or at risk for AD/ADRD.

项目摘要（总体） 预计全球阿尔茨海默病和相关痴呆症（AD/ADRD）患者人数将接近 到2050年翻三倍由于几乎没有有效的治疗方法来预防这种疾病或减缓其进展， 目前仅限于管理现有疾病和尽量减少进一步的负面结果，费用为200美元 每年10亿。《国家老年痴呆症项目法案》（NAPA）获得通过，目标是减轻负担 AD/ADRD，不仅对痴呆症患者，而且对整个社会，包括社会， 经济和卫生系统的影响。我们对政策制定者、公众 卫生规划人员和卫生保健组织可以最好地准备和应对广泛的人口影响 在我们等待治愈的同时，加速阿尔茨海默氏症人口研究中心 密歇根大学的CAPRA将专注于为政府和医疗保健提供信息的科学 本组织采取行动，应对痴呆症对老年人健康和经济福祉的负面影响 个人和人口。我们对痴呆症患者公共政策和医疗保健的关注福尔斯属于 四个相互关联的主题：1）医疗保健提供和政策对结果和护理质量的影响，2）传播 3）在质量和获得护理方面的差距，以及4）人口的创新应用 为资源分配和项目开发提供信息的数据。CAPRA领导团队是独一无二的 有能力利用其在这些主题方面的专门知识和在这些领域的机构专门知识的深度， 密歇根大学跨卫生服务，经济和人口研究，以加速和扩大 基于人群的AD/ADRD观察性研究。CAPRA的总体目标是，它将作为一个 国家资源，使当前和未来的领导人在医疗保健研究和扩大研究 交付，经济学和政策，以减少当地，国家和国际AD/ADRD的负担。到 这样做，该中心将作为一个“坡道”，以快速跟踪初级和既定的调查人员过渡到 通过资助试点研究，提供研究培训和工具， 与AD/ADRD相关的二级数据，并建立专家网络， 合作CAPRA寻求成为领先的国家资源，以促进和加速研究， 减少AD/ADRD对人口的社会、经济和健康负担。研究结果表明， 这一新中心将对卫生系统、支付者和政策制定者产生现实影响， 努力设计有效的政策，以改善日益增长的患有或有可能患有艾滋病的人口的结果。 AD/ADRD。